CS Medica

Less than 1K followers

CS Medica is a Danish company active in medical technology. The company specializes in the development of new medical treatments. The portfolio includes medical cannabis (CBD) products, with the greatest focus on dietary supplements and various treatment care. The products are used, for example, by patients suffering from psoriasis, osteoarthritis, and hair loss. The largest operations are found in the Nordic market, where the products are resold under their own brand.

ShowingAll content types

Regulatory press release1/9/2025, 7:30 AM

CS MEDICA A/S: CEO Letter: A Moment of Transition for CS MEDICA

Regulatory press release1/1/2025, 6:18 PM

Update from Chairperson: Delisting of CS MEDICA A/S from Spotlight Stock Market

Regulatory press release12/23/2024, 7:40 PM

CS MEDICA A/S: CS MEDICA Explores Listing and Strategic Options to Protect Shareholder & Company Value

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Regulatory press release12/19/2024, 8:05 PM

CS MEDICA A/S: CS MEDICA Responds to Spotlight Stock Market's Delisting Notification

Regulatory press release12/19/2024, 7:00 AM

CS MEDICA A/S: CS MEDICA's Subsidiary CANNORDIC Marks Milestone with First Invoice to Iraq

Regulatory press release11/30/2024, 3:31 PM

CS MEDICA A/S: CS MEDICA: Q4 Interim report, July - September 2024

Regulatory press release11/22/2024, 2:45 PM

CS MEDICA A/S: Update on the Share Distribution of CANNORDIC Shares

Regulatory press release11/22/2024, 1:01 PM

CS MEDICA A/S: CS MEDICA Welcomes the Danish Government's Proposal to Make the Pilot Program for Prescription-Based Medicinal Cannabis Permanent

Regulatory press release11/13/2024, 10:13 AM

CS MEDICA A/S: CS MEDICA Announces Postponement of Financial Reporting Deadlines

Regulatory press release11/12/2024, 5:18 PM

CS MEDICA A/S: Minutes of Extraordinary General Meeting

Regulatory press release11/12/2024, 7:00 AM

CS MEDICA A/S: Update on the Strategic Rationale Behind CANNORDIC IPO and Aim for Capital Increase

Regulatory press release11/11/2024, 7:00 AM

CS MEDICA A/S: CS MEDICA Expands Presence in Eastern Europe through New Partnership

Regulatory press release11/4/2024, 10:18 AM

CS MEDICA A/S: CS MEDICA Valued at 17,16 DKK (€2.30 ) per Share Ahead of German IPO, Highlighting Unique Regulatory Position and Growth Potential

Regulatory press release10/29/2024, 3:50 PM

CS MEDICA A/S: CS MEDICA Achieves Key Milestone in MDR Compliance with Finalized Classification, Solidifying Unique Market Position for Medical Devices

Regulatory press release10/28/2024, 8:16 PM

CS MEDICA A/S: Notice of Extraordinary General Meeting

Regulatory press release10/21/2024, 7:15 AM

CS MEDICA A/S Update from CEO: Progress on CANNORDIC IPO, Share Distribution & Upcoming Market Analysis

Regulatory press release10/2/2024, 2:11 PM

CS MEDICA A/S Secures Sales Approval in Azerbaijan & Georgia, Valued at 1.17 mDKK

Regulatory press release10/2/2024, 2:08 PM

CS MEDICA A/S Share Capital Increase Registered with the Danish Companies Registration Office

Regulatory press release9/30/2024, 7:31 AM

CS MEDICA A/S: CS MEDICA's Subsidiary Signs Agreement to Target the German Market, Leveraging Expertise of Nimbus Health, a Dr. Reddy's Laboratories company.

Regulatory press release9/26/2024, 2:51 PM

CS MEDICA A/S Update from CEO: Strategic Developments on CANNORDIC Planned IPO Milestones

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.